細胞表面標誌物市場－全球產業規模、佔有率、趨勢、機會、預測：按來源、產品、細胞類型、應用、地區和競爭格局分類，2021-2031年

細胞表面標誌物市場規模將從 8.1231 億美元大幅成長至 2031 年的 13.3776 億美元，複合年成長率為 8.67%。

這種強勁成長主要源自於癌症和自體免疫疾病等慢性病盛行率的不斷上升，這些疾病需要複雜的免疫表現型分析才能進行準確診斷和監測。對個人化醫療日益成長的關注進一步加劇了這一需求，因為特異性標記對於識別治療標靶和對患者進行分層至關重要。例如，預計到2025年美國將新增2,041,910例癌症病例，凸顯了基於標記物的檢測方法的巨大需求。同時，全球癌症負擔日益加重（根據世界衛生組織（WHO）統計，2022年全球報告的新增癌症病例約為2000萬例）以及愛滋病和肝炎等慢性感染疾病也是主要促進因素，這些都需要先進的工具來識別惡性細胞和表徵免疫反應。此外，對製藥和生物技術研發的大量投資——例如羅氏在 2024 年投入 130 億瑞士法郎的研發預算，以及同年美國食品藥物管理局(FDA)核准的50 種新藥——正在積極推動市場擴張，刺激對高通量篩檢和生物標記發現的需求，而這對於新的免疫療法和標靶治療至關重要。

市場促進因素

癌症和慢性感染疾病的日益普及是全球細胞表面標誌物市場的主要驅動力，這促使人們需要先進的免疫表現型分析工具來進行精確診斷和疾病監測。細胞表面標誌物對於區分惡性細胞和正常表現型，以及表徵愛滋病和肝炎等疾病中複雜的免疫反應至關重要。隨著這些疾病在全球範圍內的負擔日益加重，臨床檢查室和研究機構越來越依賴基於標誌物的檢測方法來對患者進行分層並制定個性化的治療性介入。世界衛生組織（WHO）在2024年2月發布的數據顯示，國際癌症研究機構（IARC）估計，2022年全球新增癌症病例約2000萬例，這迫切需要精準的細胞分析技術，從而推動特定抗體組合和流式細胞技術試劑的消費。同時，製藥和生技領域研發投入的大幅成長刺激了對高通量篩檢和生物標記發現的需求，從而積極促進了市場成長。生物製藥公司正大力投資於新型免疫療法和標靶治療的研發，而細胞表面標誌物在這過程中對於標靶檢驗和作用機制研究至關重要。例如，羅氏公司在2025年1月報告稱，2024會計年度的研發總投資額達到130億瑞士法郎，體現了該產業對創新的堅定承諾。這筆資金的流入直接支持了臨床試驗和藥物研發管線，進而推動了診斷標記的廣泛應用。監管方面的進展也為這種蓬勃發展的研發環境提供了支持。根據監管專業人員協會（RAPS）統計，截至2025年1月，美國食品藥物管理局（FDA）藥物評估與研究中心在2024年核准了50種新藥，凸顯了充滿活力的研發環境，也為標誌物分析提供了有力支撐。

市場挑戰

高參數流式細胞技術設備所需的大量資金投入以及抗體研發的技術複雜性是全球細胞表面標誌物市場擴張的主要障礙。實驗室和臨床中心通常面臨預算緊張的困境，這阻礙了他們購買複雜免疫表現型分析所需的硬體和試劑。此外，為確保試劑沒有交叉反應而進行的標記驗證高成本，且需要專業人員和資源，進一步加劇了這種經濟壓力。因此，這些高昂的成本限制了基於標誌物技術的應用，尤其是在資本支出受到嚴格控制的小規模研究機構。近期影響這些診斷工具最終用戶的資金籌措趨勢也凸顯了這種購買力下降的現狀。據美國醫學院協會 (AAMC) 稱，與上年度相比，美國國立衛生研究院 (NIH) 計劃在 2025 年削減美國研究機構近 50 億美元的研究津貼。聯邦政府大規模削減經費迫使學術機構和臨床檢查室縮減營運規模，常常導致昂貴的檢測平台被延後或取消。當核心研究經費減少時，市場會直接放緩，因為維持專業細胞標記分析所需的高昂營運成本變得不可能。

市場趨勢

人工智慧 (AI) 與生物標記發現的融合正在重塑細胞表面蛋白的鑑定和檢驗方式。機器學習演算法正被擴大應用於分析海量免疫表現型資料集，以預測抗原相互作用和表面表達模式，推動產業擺脫傳統的勞動密集型篩檢方法。這種電腦驅動的變革將使製藥研發人員能夠發現先前因生物複雜性而難以發現的新型治療標靶。例如，根據 2026 年 1 月《製藥技術》雜誌報道，賽諾菲已與 Earendil Labs 合作，投資高達 25.6 億美元，利用人工智慧驅動的藥物發現平台來識別自體免疫疾病的雙特異性抗體和表面靶點。同時，將表面標誌物分析與基因測序結合的「單細胞多體學學分析」方法正在改變市場動態。這種方法在單細胞層面將表現型表面表達與潛在的遺傳因素關聯起來，從而提供僅靠流式細胞技術無法實現的細胞異質性全面視圖。隨著對這類整合工作流程的需求日益成長，企業正在進行策略性業務整合，以融合蛋白質體學和基因組學技術。例如，根據Standard BioTools在2025年6月發布的報告，該公司已同意將其SomaLogic蛋白質組學業務以3.5億美元的預付款出售給Illumina。此舉旨在整合高通量蛋白質分析和次世代定序能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球細胞表面標誌物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 供應來源（小鼠、大鼠）
  • 產品類別（抗體、PCR晶片、其他）
  • 細胞類型特異性標記（B細胞表面標誌物、單核細胞表面標誌物、NK細胞表面標誌物、T細胞表面標誌物）
  • 按應用領域（臨床、研究）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美細胞表面標誌物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲細胞表面標誌物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區細胞表面標誌物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲細胞表面標誌物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美細胞表面標誌物市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章：全球細胞表面標誌物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Thermo Fisher Scientific Inc.
• QIAGEN NV
• Becton, Dickinson and Company.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc
• Abcam plc
• GenScript Biotech Corporation
• BioLegend, Inc.
• Merck KGaA

第16章 策略建議

第17章：關於研究公司及免責聲明

The global market for cell surface markers, crucial for identifying and classifying cell types through specialized proteins and carbohydrates on their plasma membranes, is projected to expand significantly from USD 812.31 Million in 2025 to USD 1337.76 Million by 2031, demonstrating an 8.67% CAGR. This robust growth is primarily fueled by the increasing prevalence of chronic diseases, such as cancer and autoimmune disorders, which necessitates advanced immunophenotyping for accurate diagnosis and monitoring. The rising emphasis on personalized medicine further amplifies this demand, as specific markers are vital for pinpointing therapeutic targets and stratifying patients; for instance, an estimated 2,041,910 new cancer cases projected in the United States in 2025 highlight the substantial need for marker-based assays. Concurrently, the escalating global burden of cancer, with approximately 20 million new cases worldwide in 2022 according to the World Health Organization, and chronic infectious diseases like HIV/AIDS and hepatitis, is a key driver, demanding sophisticated tools to differentiate malignant cells and characterize immune responses. Furthermore, substantial investment in pharmaceutical and biotechnology research and development, exemplified by Roche's CHF 13.0 billion R&D expenditure in 2024 and the U.S. FDA's approval of 50 novel drugs in the same year, is actively propelling market expansion by driving demand for high-throughput screening and biomarker discovery essential for novel immunotherapies and targeted drugs.

Market Driver

The escalating prevalence of cancer and chronic infectious diseases stands as a primary catalyst for the Global Cell Surface Markers Market, necessitating advanced immunophenotyping tools for accurate diagnosis and disease monitoring. Cell surface markers are indispensable for distinguishing malignant cells from healthy phenotypes and for characterizing complex immune responses in conditions such as HIV/AIDS and hepatitis. As the global burden of these pathologies expands, clinical laboratories and research institutions increasingly rely on marker-based assays to stratify patients and tailor therapeutic interventions. According to the World Health Organization, in February 2024, the International Agency for Research on Cancer estimated that approximately 20 million new cancer cases occurred globally in 2022, creating a critical need for precise cellular analysis technologies that drive the consumption of specific antibody panels and flow cytometry reagents. Simultaneously, the massive expansion of pharmaceutical and biotechnology research and development expenditure is actively propelling market growth by fueling demand for high-throughput screening and biomarker discovery. Biopharmaceutical companies are heavily investing in R&D to develop novel immunotherapies and targeted drugs, a process that relies on cell surface markers for target validation and mechanism-of-action studies. For instance, according to Roche, in January 2025, the company reported a total research and development investment of CHF 13.0 billion for the 2024 fiscal year, reflecting the industry's commitment to innovation. This financial influx directly supports clinical trials and discovery pipelines, subsequently increasing the utilization of diagnostic markers. This robust development environment is further evidenced by regulatory milestones; according to the Regulatory Affairs Professionals Society (RAPS), in January 2025, the U.S. FDA's Center for Drug Evaluation and Research approved 50 novel drugs in 2024, highlighting the active research landscape that sustains the demand for marker analysis.

Market Challenge

The substantial financial investment required for high-parameter flow cytometry instruments and the technical intricacies of antibody development present a formidable barrier to the expansion of the global cell surface markers market. Laboratories and clinical centers often operate under strict budgetary limitations, which impedes their ability to procure the necessary hardware and reagents for complex immunophenotyping. This economic pressure is exacerbated by the high costs associated with validating markers to ensure they are free from reagent cross-reactivity, a process that demands specialized personnel and resources. Consequently, these prohibitive costs restrict the adoption of marker-based technologies, particularly in smaller research facilities where capital expenditure is tightly controlled. This contraction in purchasing power is substantiated by recent funding trends that directly affect the end-users of these diagnostic tools. According to the Association of American Medical Colleges, in 2025, the National Institutes of Health committed nearly $5 billion less in research grants to United States institutions compared to the previous year. A reduction of this magnitude in federal support forces academic and clinical laboratories to scale back operations, often delaying or cancelling the acquisition of expensive assay platforms. When core research funding is diminished, the market experiences a direct deceleration as institutions are unable to sustain the high operational costs required for specialized cell marker analysis.

Market Trends

The Integration of Artificial Intelligence in Biomarker Discovery is reshaping how cell surface proteins are identified and validated. Machine learning algorithms are increasingly deployed to analyze massive immunophenotyping datasets to predict antigen interactions and surface expression patterns, moving the industry beyond traditional, labor-intensive screening methods. This computational shift allows pharmaceutical developers to uncover novel therapeutic targets that were previously obscured by biological complexity. Illustrating this adoption, according to Pharmaceutical Technology, January 2026, Sanofi entered a partnership with Earendil Labs valued at up to $2.56 billion to utilize an AI-driven discovery platform for identifying bispecific antibodies and surface targets for autoimmune diseases. Simultaneously, a Shift Towards Single-Cell Multi-Omics Profiling is altering market dynamics, as researchers combine surface marker analysis with genomic sequencing. This approach correlates phenotypic surface expression with underlying genetic drivers at the single-cell level, providing a comprehensive view of cellular heterogeneity that flow cytometry alone cannot achieve. The demand for these integrated workflows is driving strategic business consolidations to merge protein and genomic technologies. For instance, according to Standard BioTools, June 2025, the company agreed to sell its SomaLogic proteomics business to Illumina for an upfront payment of $350 million, aiming to integrate high-plex protein analysis with next-generation sequencing capabilities.

Key Market Players

• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Becton, Dickinson and Company.
• Danaher Corporation
• F. Hoffmann-La Roche AG
• Bio-Rad Laboratories, Inc
• Abcam plc
• GenScript Biotech Corporation
• BioLegend, Inc.
• Merck KGaA

Report Scope

In this report, the Global Cell Surface Markers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell Surface Markers Market, By Source

• Mice
• Rats

Cell Surface Markers Market, By Product

• Antibodies
• PCR Arrays
• Others

Cell Surface Markers Market, By Cell Type

• B Cell Surface Markers
• Monocyte Cell Surface Markers
• NK Cell Surface Markers
• T Cell Surface Markers

Cell Surface Markers Market, By Application

• Clinical
• Research

Cell Surface Markers Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell Surface Markers Market.

Available Customizations:

Global Cell Surface Markers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Cell Surface Markers Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Source (Mice, Rats)
  • 5.2.2. By Product (Antibodies, PCR Arrays, Others)
  • 5.2.3. By Cell Type (B Cell Surface Markers, Monocyte Cell Surface Markers, NK Cell Surface Markers, T Cell Surface Markers)
  • 5.2.4. By Application (Clinical, Research)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Cell Surface Markers Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Source
  • 6.2.2. By Product
  • 6.2.3. By Cell Type
  • 6.2.4. By Application
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cell Surface Markers Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Source
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Cell Type
      • 6.3.1.2.4. By Application
  • 6.3.2. Canada Cell Surface Markers Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Source
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Cell Type
      • 6.3.2.2.4. By Application
  • 6.3.3. Mexico Cell Surface Markers Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Source
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Cell Type
      • 6.3.3.2.4. By Application

7. Europe Cell Surface Markers Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Source
  • 7.2.2. By Product
  • 7.2.3. By Cell Type
  • 7.2.4. By Application
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Cell Surface Markers Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Source
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Cell Type
      • 7.3.1.2.4. By Application
  • 7.3.2. France Cell Surface Markers Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Source
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Cell Type
      • 7.3.2.2.4. By Application
  • 7.3.3. United Kingdom Cell Surface Markers Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Source
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Cell Type
      • 7.3.3.2.4. By Application
  • 7.3.4. Italy Cell Surface Markers Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Source
      • 7.3.4.2.2. By Product
      • 7.3.4.2.3. By Cell Type
      • 7.3.4.2.4. By Application
  • 7.3.5. Spain Cell Surface Markers Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Source
      • 7.3.5.2.2. By Product
      • 7.3.5.2.3. By Cell Type
      • 7.3.5.2.4. By Application

8. Asia Pacific Cell Surface Markers Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Source
  • 8.2.2. By Product
  • 8.2.3. By Cell Type
  • 8.2.4. By Application
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cell Surface Markers Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Source
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Cell Type
      • 8.3.1.2.4. By Application
  • 8.3.2. India Cell Surface Markers Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Source
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Cell Type
      • 8.3.2.2.4. By Application
  • 8.3.3. Japan Cell Surface Markers Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Source
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Cell Type
      • 8.3.3.2.4. By Application
  • 8.3.4. South Korea Cell Surface Markers Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Source
      • 8.3.4.2.2. By Product
      • 8.3.4.2.3. By Cell Type
      • 8.3.4.2.4. By Application
  • 8.3.5. Australia Cell Surface Markers Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Source
      • 8.3.5.2.2. By Product
      • 8.3.5.2.3. By Cell Type
      • 8.3.5.2.4. By Application

9. Middle East & Africa Cell Surface Markers Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Source
  • 9.2.2. By Product
  • 9.2.3. By Cell Type
  • 9.2.4. By Application
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Cell Surface Markers Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Source
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Cell Type
      • 9.3.1.2.4. By Application
  • 9.3.2. UAE Cell Surface Markers Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Source
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Cell Type
      • 9.3.2.2.4. By Application
  • 9.3.3. South Africa Cell Surface Markers Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Source
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Cell Type
      • 9.3.3.2.4. By Application

10. South America Cell Surface Markers Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Source
  • 10.2.2. By Product
  • 10.2.3. By Cell Type
  • 10.2.4. By Application
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Cell Surface Markers Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Source
      • 10.3.1.2.2. By Product
      • 10.3.1.2.3. By Cell Type
      • 10.3.1.2.4. By Application
  • 10.3.2. Colombia Cell Surface Markers Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Source
      • 10.3.2.2.2. By Product
      • 10.3.2.2.3. By Cell Type
      • 10.3.2.2.4. By Application
  • 10.3.3. Argentina Cell Surface Markers Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Source
      • 10.3.3.2.2. By Product
      • 10.3.3.2.3. By Cell Type
      • 10.3.3.2.4. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cell Surface Markers Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Thermo Fisher Scientific Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. QIAGEN N.V.
• 15.3. Becton, Dickinson and Company.
• 15.4. Danaher Corporation
• 15.5. F. Hoffmann-La Roche AG
• 15.6. Bio-Rad Laboratories, Inc
• 15.7. Abcam plc
• 15.8. GenScript Biotech Corporation
• 15.9. BioLegend, Inc.
• 15.10. Merck KGaA

16. Strategic Recommendations

17. About Us & Disclaimer